I-Mab Biopharma and ABL Bio Corporation have entered into a strategic partnering agreement for ABL Bio to in-license the global rights excluding Greater China to I-Mab’s bispecific antibodies (BsAb) of undisclosed target with licensing payments of approximately $100 million in total. The two companies also agreed on a collaboration to co-develop additional BsAbs as part of the partnership.    Under the terms of the agreement, ABL Bio will pay $2.5 million in upfront payment. I-Mab wi...